

others.

among

PROSPECTS FOR THE USE OF NANOCRYSTALLINE CERIUM DIOXIDE AS A PREBIOTIC FOR MICROBIOME CORRECTION

Babenko L.P., Bubnov R.V., Tymoshok N.O., Lazarenko L.M., Spivak M.Ja.

E-mail: <u>babenkolidiia@gmail.com</u>

Zabolotny Institute of Microbiology and Virology of NAS of Ukraine, Kyiv, Ukraine



Two lines of mice were used in the study: BALB/c mice (6–8 weeks, 18–24 g) and CBA mice (11–12 months, 20–26 g); experimental animals were fed by fatenriched diet 3 weeks before the evaluation. Animals were divided into groups to test probiotic strains and nanoceria. All groups received probiotic strains orally and cerium dioxide orally or intravenously in various composition.

A group of untreated animals was used as a control. Cholesterol level and gut microbiota of mice were studied.

Results

Cerium dioxide nanoparticles, probiotic strain *L. casei* IMV B-7280, and composition *B. animalis* VKB/*B. animalis* VKL applied separately and in different combinations all reduced at different levels free and bound cholesterol in blood serum of mice fed by fat-enriched diet. The combination of 0.01 M nanoceria and probiotic strain

The levels of free cholesterol in the serum of young BALB / c mice

Day of study /	doy 4	dov 0	dov 15	day 21	day 20
group of animals	day 4 day 9 day 15 day 21 day 30 mg/ml				
Intact animals	4.82 ± 0.36	4.34 ± 0.31	4.61 ± 0.18	5.01 ± 0.11	4.46 ± 0.14
Animals on the FED	12.33 ± 0.77	11.27 ± 0.29	9.77 ± 0.37	8.68 ± 0.71	9.21 ± 0.53
FED + 0,1 M CeO ₂ orally	11.18 ± 0.08	8.98 ± 0.36	9.88 ± 0.29	9.88 ± 0.19	7.36 ± 0.48
FED + 0,01 M CeO ₂ orally	8.40 ± 0.06	5.70 ± 0.17	5.49 ± 0.11	5.04 ± 0.28	4.79 ± 0.35
FED + 0,001 M CeO ₂ orally	9.42 ± 0.33	7.50 ± 0.36	7.04 ± 0.18	5.72 ± 0.20	5.31 ± 0.61
FED + 0,1 M CeO ₂ + L. casei IMV B-7280 orally	8.36 ± 0.22	8.40 ± 0.28	6.47 ± 0.56	5.31 ± 0.31	6.17 ± 0.34
FED + 0,01 M CeO ₂ + L. casei IMV B-7280 orally	6.32 ± 1.11	4.83 ± 0.46	3.01 ± 0.09	2.23 ± 0.48	3.88 ± 0.25
FED + 0,001 M CeO ₂ + L. casei IMV B-7280 orally	7.54 ± 0.36	6.40 ± 0.53	5.96 ± 0.74	4.09 ± 0.32	3.52 ± 0.49
FED + 0,1 M CeO ₂ + B. animalis VKB / B. animalis VKL orally	10.03 ± 0.43	8.80 ± 0.22	7.98 ± 0.04	6.36 ± 0.30	5.93 ± 0.20
FED + 0,01 M CeO ₂ + B. animalis VKB /B. animalis VKL orally	8.65 ± 0.20	8.37 ± 0.10	7.11 ± 0.08	6.38 ± 0.14	5.62 ± 0.11
FED + B. animalis VKB /B. animalis VKL orally	10.03 ± 0.29	8.98 ± 0.24	8.11 ± 0.16	6.93 ± 0.05	7.01 ± 0.15
FED + L. casei IMV B- 7280 orally	8.41 ± 0.06	7.19 ± 0.15	5.99 ± 0.25	4.53 ± 0.49	3.15 ±0.23
FED + B. animalis VKB /B. animalis VKL orally	9.72 ± 0.22	8.54 ± 0.08	6.93 ± 0.19	4.41 ± 0.60	4.19 ±0.10

<u>Is nanoceria a prebiotic</u>?


- •Nanoceria demonstrate **no suppressive** effects on of the growth of probiotic bacteria strains in size, shape and concentrations used in current experiment (*unpublished data*);
- •Nanoceria has strong potential to modulate metabolism and oxidative stress in the host cells including intestinal mucosa and beyond gut and to modulate probiotic activity;
- •Biological effects to reduce cholesterol levels might effect on **development of favorable conditions for probiotic strains** in particular in the gut;
- •The strongest effect of nanoceria was observed when introduced into the vein at a concentration of 0.01M CeO₂; intravenous administration was more effective vs oral use;
- •Effects of nanoceria are size-, shape-, pH-, concentration- and other parameters-dependent;
- •Antibacterial activity of cerium oxide nanoparticles is strain-selective and size-dependent, depends on local environment, altering the pH;
- •Interaction between nanoparticles and bacterial pili depends on pH:
- Nanoceria can promote growth of bacteria and cells.


mature animals. Oral administration of CeO_2 applied alone reduced the number of microscopic fungi in the gut of mice and Gram-positive cocci (staphylococci and/or streptococci). Application of *L. casei* IMV B-7280 as a probiotic strain increased most significantly the number of lactobacilli and bifidobacteria in the gut of mice. The most significant normalization of gut microbiota was observed after oral administration of alternatively either *L. casei* IMV B-7280 + 0.1 M CeO_2 or *L. casei* IMV B-7280 + 0.01 M CeO_2 . The presented results provide novel insights into

L. casei IMV B-7280 resulted in the fastest

cholesterol level decrease in both young and

mechanisms behind nutritional supplements and open new perspectives for application of combined with substances probiotics demonstrating prebiotic qualities benefiting, therefore, the host health. If validated in a largescale clinical study, this approach might be instrumental for primary and secondary prevention in obese individual and patients diagnosed with diabetes. To this end, individualized prediction and treatments tailored to the person are strongly recommended to benefit the health condition.





Background

Microbiome modulation is a pillar intervention

to treat metabolic syndrome and cascade of

related pathologies such as atherosclerosis,

Bifidobacterium probiotic strains demonstrate

efficacy to reduce obesity, dyslipidemia, and

Lactobacillus

and



Nanoceria (nanocrystalline cerium dioxide, ceria

nanoparticles, nCeO2) was proved to be able to

participate in biological processes as a regulator of

reactive oxygen species and free radicals acceptor and

its efficacy for number of biomedical applications

Ultrasound during experiment – liver (B), kidney (C)

The study was conducted with the support of the State Agency on Science, Innovations and Informatization of Ukraine.